Cassidy, F, Ahearn, E, Carroll, BJ.
Elevated frequency of diabetes mellitus in hospitalized
manic-depressive patients. Am J
1999; 156: 1417–20.
Prevalence of diabetes in a manic-depressive
population. Compr Psychiatry
1980; 21: 270–5.
McIntyre, RS, Konarski, JZ, Misener, VL, Kennedy, SH.
Bipolar disorder and diabetes mellitus: epidemiology,
etiology, and treatment implications. Ann Clin
Osby, U, Brandt, L, Correia, N, Ekbom, A, Sparen, P.
Excess mortality in bipolar and unipolar disorder in
Sweden. Arch Gen Psychiatry
2001; 5: 844–50.
Ruzickova, M, Slaney, C, Garnham, J, Alda, M.
Clinical features of bipolar disorder with and without
comorbid diabetes mellitus. Can J
2003; 48: 458–61.
Calkin, C, Van de Velde, C, Ruzickova, M, Slaney, C, Garnham, J, Hajek, T, et al.
Can body mass index help predict outcome in patients with
bipolar disorder? Bipolar Disord
2009; 11: 650–6.
Kemp, DE, Gao, K, Chan, PK, Ganocy, SJ, Findling, RL, Calabrese, JR.
Medical comorbidity in bipolar disorder: relationship between
illnesses of the endocrine/metabolic system and treatment
outcome. Bipolar Disord
2010; 12: 404–13.
Endicott, J, Spitzer, RL.
A diagnostic interview: the schedule for affective disorders
and schizophrenia. Arch Gen Psychiatry
1978; 35: 837–44.
Spitzer, RL, Endicott, J, Robins, E.
Research diagnostic criteria: rationale and
reliability. Arch Gen Psychiatry
1978; 35: 773–82.
American Psychiatric Association. Diagnostic and
Statistical Manual of Mental Disorders (4th
edn, text revision) (DSM-IV-TR).
Rucker, J, Newman, S, Gray, J, Gunasinghe, C, Broadbent, M, Brittain, P, et al.
OPCRIT+: an electronic system for psychiatric diagnosis and
data collection in clinical and research settings.
Br J Psychiatry
2011; 199: 151–5.
Denicoff, KD, Leverich, GS, Nolen, WA, Rush, AJ, McElroy, SL, Keck, PE, et al.
Validation of the prospective NIMH-Life-Chart Method
(NIMH-LCM-p) for longitudinal assessment of bipolar
illness. Psychol Med
2000; 30: 1391–7.
Denicoff, KD, Ali, SO, Sollinger, AB, Smith-Jackson, EE, Leverich, GS, Post, RM.
Utility of the daily prospective National Institute of Mental
Health Life-Chart Method (NIMH-LCM-p) ratings in clinical trials of
bipolar disorder. Depress Anxiety
Grof, P, Duffy, A, Cavazzoni, P, Grof, E, Garnham, J, MacDougall, M, et al.
Is response to prophylactic lithium a familial
trait? J Clin Psychiatry
2002; 63: 942–7.
Garnham, J, Munro, A, Slaney, C, MacDougall, M, Passmore, M, Duffy, A, et al.
Prophylactic treatment response in bipolar disorder: results
of a naturalistic observation study. J Affect
2007; 104: 185–90.
Manchia, M, Adli, M, Akula, N, Ardau, R, Aubry, JM, Backlund, L, et al.
Assessment of response to lithium maintenance treatment in
bipolar disorder: a Consortium on Lithium Genetics (ConLiGen)
report. PLoS One
Jones, SH, Thornicroft, G, Coffey, M, Dunn, G.
A brief mental health outcome scale – reliability and
validity of the Global Assessment of Functioning (GAF).
Br J Psychiatry
1995; 166: 654–9.
Andreasen, NC, Endicott, J, Spitzer, RL, Winokur, G.
The family history method using diagnostic criteria.
Reliability and validity. Arch Gen
1977; 34: 1229–35.
Katsuki, A, Sumida, Y, Gabazza, EC, Murashima, S, Furuta, M, Araki-Sasaki, R, et al.
Homeostasis model assessment is a reliable indicator of
insulin resistance during follow-up of patients with type 2
diabetes. Diabetes Care
2001; 24: 362–5.
Wallace, TM, Levy, JC, Matthews, DR.
Use and abuse of HOMA modeling.
2004; 27: 1487–95.
Esteghamati, A, Ashraf, H, Khalilzadeh, O, Zandieh, A, Nakhjavani, M, Rashidi, A, et al.
Optimal cut-off of homeostasis model assessment of insulin
resistance (HOMA-IR) for the diagnosis of metabolic syndrome: third
national surveillance of risk factors of non-communicable diseases in
Iran (SuRFNCD-2007). Nutr Metab
Wongwananuruk, T, Rattanachaiyanont, M, Leerasiri, P, Indhavivadhana, S, Techatraisak, K, Angsuwathana, S, et al.
The usefulness of homeostatic measurement assessment-insulin
resistance (HOMA-IR) for detection of glucose intolerance in Thai women
of reproductive age with polycystic ovary syndrome.
Int J Endocrinol
Matthews, DR, Hosker, JP, Rudenski, AS, Naylor, BA, Treacher, DF, Turner, RC.
Homeostasis model assessment: insulin resistance and
beta-cell function from fasting plasma glucose and insulin concentrations
in man. Diabetologia
1985; 28: 412–9.
Uher, R, Tansey, KE, Malki, K, Perlis, RH.
Biomarkers predicting treatment outcome in depression: what
is clinically significant?
2012; 13: 233–40.
Yood, MU, DeLorenze, G, Quesenberry, CP Jr, Oliveria, SA, Tsai, AL, Willey, VJ, et al.
The incidence of diabetes in atypical antipsychotic users
differs according to agent: results from a multisite epidemiologic
study. Pharmacoepidemiol Drug Saf
2009; 18: 791–9.
Wallum, BJ, Taborsky, GJ Jr, Porte, D Jr, Figlewicz, DP, Jacobson, L, Beard, JC, et al.
Cerebrospinal fluid insulin levels increase during
intravenous insulin infusions in man. J Clin
1987; 64: 190–4.
Craft, S, Watson, GS.
Insulin and neurodegenerative disease: shared and specific
mechanisms. Lancet Neurol
2004; 3: 169–78.
Hajek, T, Calkin, C, Blagdon, R, Slaney, C, Alda, M.
Type 2 Diabetes mellitus: a potentially modifiable risk
factor for neurochemical brain changes in bipolar
disorders. Biol Psychiatry
2013; Nov 13 (Epub ahead of print).
Hajek, T, Calkin, C, Blagdon, R, Slaney, C, Uher, R, Alda, M.
Insulin resistance, diabetes mellitus and brain structure in
2014; June 19 (Epub ahead of print).
McIntyre, RS, Danilewitz, M, Liauw, SS, Kemp, DE, Nguyen, HT, Kahn, LS, et al.
Bipolar disorder and metabolic syndrome: an international
perspective. J Affect Disord
2010; 126: 366–87.
Kaidanovich-Beilin, O, Cha, DS, McIntyre, RS.
Crosstalk between metabolic and neuropsychiatric
disorders. F1000 Biol Rep
Calkin, CV, Gardner, DM, Ransom, T, Alda, M.
The relationship between bipolar disorder and type 2
diabetes: more than just co-morbid disorders. Ann
2012; 45: 171–81.